ScholarLens Back to search
2023•Unpublished venueOpen access

Supplementary Figure 1 from Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) Trial in Acquired PARP Inhibitor–Resistant Homologous Recombination–Deficient Ovarian Cancer

Stephanie L. Wethington, Payal Deepak Shah, Lainie P. Martin, Janos Laszlo Tanyi, Nawar Latif, Mark Aloysuis Morgan, Drew A. Torigian, Diego Rodriguez, Simon A. Smith, Emma Jane Dean, Susan M. Domchek, Ronny Drapkin, Ie‐Ming Shih, Eric J. Brown, Wei‐Ting Hwang, Deborah Kay Armstrong, Stephanie L. Gaillard, Robert Lawrence Giuntoli, Fiona A. Simpkins

Open full text 0 citations

Abstract

Trial schema

About this research paper

What this paper is about

Trial schema

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Trial schema

Key concepts: Olaparib, PARP inhibitor, Homologous recombination, Poly ADP ribose polymerase, Ovarian cancer, Medicine, Cancer research, Oncology

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Supplementary Figure 1 from Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) Trial in Acquired PARP Inhibitor–Resistant Homologous Recombination–Deficient Ovarian Cancer — Research Paper | ScholarLens